Do dopamine partial agonists have partial efficacy as antipsychotics?
Stahl
Stephen M
SM
Department of Psychiatry, University of California-San Diego, La Jolla, CA, USA.
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D001921:Brain / Q000187:drug effects; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D018492:Dopamine Antagonists / Q000009:adverse effects; D065127:Dopamine D2 Receptor Antagonists; D006801:Humans; D019964:Mood Disorders / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy*; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use; D017448:Receptors, Dopamine D2 / Q000819:agonists*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D010879:Piperazines; D015363:Quinolones; D017448:Receptors, Dopamine D2; D000068180:Aripiprazole